. 2022 Jan;42(1):15-26. doi: 10.1002/pd.6047. Epub 2021 Oct 12. https://pubmed.ncbi.nlm.nih.gov/34550624/
Development of standard definitions and grading for Maternal and Fetal Adverse Event Terminology
Rebecca N Spencer 1 2, Kurt Hecher 3, Gill Norman 4 5, Karel Marsal 6, Jan Deprest 2 7, Alan Flake 8, Francesc Figueras 9 10, Christoph Lees 11, Steve Thornton 12, Kathleen Beach 13, Marcy Powell 14, Fatima Crispi 9 10, Anke Diemert 15, Neil Marlow 2, Donald M Peebles 2 16, Magnus Westgren 17, Helena Gardiner 18, Eduard Gratacos 10 19, Jana Brodszki 6, Albert Batista 9, Helen Turier 20, Mehali Patel 21 22, Beverley Power 23, James Power 23, Gillian Yaz 24, Anna L David 2 16Affiliations expand
- PMID: 34550624
- DOI: 10.1002/pd.6047
Objective: Adverse event (AE) monitoring is central to assessing therapeutic safety. The lack of a comprehensive framework to define and grade maternal and fetal AEs in pregnancy trials severely limits understanding risks in pregnant women. We created AE terminology to improve safety monitoring for developing pregnancy drugs, devices and interventions.
Method: Existing severity grading for pregnant AEs and definitions/indicators of ‘severe’ and ‘life-threatening’ conditions relevant to maternal and fetal clinical trials were identified through a literature search. An international multidisciplinary group identified and filled gaps in definitions and severity grading using Medical Dictionary for Regulatory Activities (MedDRA) terms and severity grading criteria based on Common Terminology Criteria for Adverse Event (CTCAE) generic structure. The draft criteria underwent two rounds of a modified Delphi process with international fetal therapy, obstetric, neonatal, industry experts, patients and patient representatives.
Results: Fetal AEs were defined as being diagnosable in utero with potential to harm the fetus, and were integrated into MedDRA. AE severity was graded independently for the pregnant woman and her fetus. Maternal (n = 12) and fetal (n = 19) AE definitions and severity grading criteria were developed and ratified by consensus.
Conclusions: This Maternal and Fetal AE Terminology version 1.0 allows systematic consistent AE assessment in pregnancy trials to improve safety.
© 2021 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.